Merck balances massive new drug launches against accelerating patent cliffs
- KEYTRUDA QLEX generated $830 million in Q3 2026, defending the core oncology franchise.
- WINREVAIR sales accelerated to $694 million in Q3 2026, marking it as a critical cardiovascular growth driver.
- LIPFENDRA saw strong early adoption with over 11,000 prescriptions in its launch phase.
- Management expects over $2 billion in revenue headwinds in 2027 due to older drugs losing exclusivity.
- A Dutch intellectual property injunction temporarily halted KEYTRUDA QLEX supply in select European markets.
A race between new launches and old cliffs
Merck is executing a portfolio transition, and the bridge to its future is taking shape. KEYTRUDA remains the core profit engine, while WINREVAIR is proving to be a massive cardiovascular growth driver with $694 million in Q3 2026 sales. The recent launch of LIPFENDRA adds another major asset, seeing over 11,000 prescriptions early on.
The challenge is the sheer size of the revenue gap the company must fill. Multiple generic versions of BRIDION have now entered the market. Combined with losses for JANUVIA and Adempas, management expects over $2 billion in revenue headwinds for 2027.
The bull case is strengthening because Merck is successfully defending its core with KEYTRUDA QLEX and building new revenue streams fast enough to offset older product losses. The company is also heavily augmenting its pipeline via multi-billion dollar acquisitions like Terns and Cidara.
The bear case centers on near-term margin pressure and execution risks. If LIPFENDRA adoption stalls or if international pricing laws compress margins, the company could struggle. A new Dutch injunction against KEYTRUDA QLEX also highlights the fragility of the transition in Europe.
Science, sales, and heavy reinvestment
Merck discovers, develops, makes, and sells medicines and vaccines. Most sales come from human health products sold to drug wholesalers, retailers, hospitals, governments, and health plans. A smaller but growing Animal Health business sells medicines, vaccines, and monitoring tools for livestock and pets.
The model works best when Merck owns protected drugs with strong demand. Patents and regulatory exclusivity help protect pricing and market share for a time. When that protection ends, generic or competing products can take a large share quickly, as seen with BRIDION.
Merck is actively preparing for that cycle. It deployed $16 billion in the first half of 2026 to acquire Terns and Cidara, aiming to augment its pipeline. Its 2025 Restructuring Program is also meant to generate about $3.0 billion in annual savings by the end of 2027, which the company is reinvesting into these new growth areas.
That plan adds discipline, but it also shows the pressure. Merck must keep funding expensive research while replacing revenue from older products and handling new international pricing pressures, like Germany's recent health care reform law.
The drugs that matter most
KEYTRUDA
KEYTRUDA is Merck's lead cancer drug and the main profit engine. Management has framed the drug as central to growth through its peak years.
Keytruda Qlex
Keytruda Qlex is the subcutaneous version of KEYTRUDA. It generated $830 million in Q3 2026 and helps defend the franchise against future competition.
WINREVAIR
WINREVAIR treats pulmonary arterial hypertension. Sales reached $694 million in Q3 2026, making it the clearest new launch success.
LIPFENDRA
LIPFENDRA is an oral PCSK9 inhibitor to help reduce LDL cholesterol. It saw over 11,000 early prescriptions and serves as a massive new primary care asset.
GARDASIL and GARDASIL 9
GARDASIL is Merck's HPV vaccine franchise. It stabilized globally in 2026 after suffering sharp demand drops in China.
JANUVIA and JANUMET
JANUVIA and JANUMET are diabetes products now facing generic competition. They lost U.S. market exclusivity in May 2026.
BRIDION
BRIDION is used to reverse certain anesthesia effects after surgery. Multiple generic competitors have now entered the market, eroding sales.
Animal Health
Animal Health sells veterinary medicines, vaccines, and health management tools. It continues to deliver solid sales growth across livestock and companion animal portfolios.
Mostly human health
Mix is based on recent reportable segment sales. The human health division drives the vast majority of revenue, heavily weighted toward oncology and cardiometabolic drugs.
What could break the story
The 2027 revenue cliff
High impact · High oddsManagement guided to over $2 billion in revenue headwinds for 2027 from older products. With multiple generic competitors now in the market for BRIDION, the revenue hit will be substantial and immediate.
European IP injunctions on KEYTRUDA QLEX
Medium impact · Medium oddsA Dutch intellectual property ruling temporarily halted KEYTRUDA QLEX supply in several key European markets. If the injunction holds or expands, it could slow the critical transition away from the original KEYTRUDA formulation.
LIPFENDRA adoption stalls
High impact · Medium oddsThe bull case requires LIPFENDRA to scale into a massive growth driver. If primary care physician inertia and access hurdles limit its uptake against entrenched generic statins and injectable PCSK9s, Merck will lose a key growth pillar.
Pricing pressure expands
Medium impact · High oddsThe Inflation Reduction Act subjects JANUVIA, JANUMET, and LENVIMA to U.S. government price setting. Internationally, Germany passed the GKV-BStabG law, which will exert significant downward pressure on sales starting in 2027. Lower prices reduce margins even when demand stays healthy.
Pipeline spending fails to pay off
High impact · Medium oddsMerck is spending heavily to acquire future products, deploying $16 billion in the first half of 2026 for Terns and Cidara. If late-stage data disappoints, the company may spend heavily without filling the late-decade revenue gap.
In one breath
What does Merck make?
Merck makes prescription medicines, vaccines, and animal health products. Its most important product is KEYTRUDA, a cancer drug, but it also sells vaccines like GARDASIL and newer medicines like WINREVAIR and LIPFENDRA.
What is Merck doing about the patent cliffs?
The company is launching new drugs like WINREVAIR and LIPFENDRA. It is also buying other companies, spending $16 billion in early 2026 to acquire Terns and Cidara for their drug pipelines.
Why do WINREVAIR and LIPFENDRA matter so much?
They are Merck's clearest new growth drivers to replace older drugs. WINREVAIR reached $694 million in Q3 2026 sales, and LIPFENDRA gives the company a massive new primary care asset.
What is the main debate on Merck stock?
The debate is whether Merck can replace older product sales fast enough. Bulls point to KEYTRUDA QLEX, new drug launches, and recent acquisitions. Bears point to mid-2026 generic losses and international pricing pressures.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - General companies
Companies near Merck & Co., Inc. in Finn's Drug Manufacturers - General industry ranking.

